These findings suggest that crizotinib may not confer clinical benefits for ES-SCLC patients with ROS1 fusions, whereas immuno-chemotherapy may prove to be a more effective therapeutic strategy for this patient cohort. Here, ROS1 is linked to small cell lung carcinoma.